secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lakewood-Amedex Biotherapeutics Inc. (LABT)
CIK:        0002079272
Form:       8-K
Filed at:   2026-09-28T21:49:48+00:00
Accession:  0001213900-26-104177
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.07
LLM model:  deepseek-v4.1-flash:cloud@v2

Lakewood-Amedex holders approve raising authorized shares to 100M and reverse split up to 1:20
--------------------------------------------------------------------------------

- Stockholders approved increasing authorized common stock from 12,500,000 to 100,000,000 shares (927,022 for, 341,843 against, 711 abstain).
- Board authorized, at its discretion, to effect one or more reverse stock splits at a cumulative ratio not exceeding 1-for-20 (922,614 for, 333,546 against).
- 2020 Equity Incentive Plan amended to raise shares issuable thereunder to 400,000 (951,373 for, 317,012 against, 1,191 abstain).
- All four nominees elected as directors: Kelvin Cooper, Doug Manion, Leonard J. DeRoma and Joseph Tucker, each with roughly 939,000-976,000 votes for.
- CBIZ CPAs P.C. ratified as independent auditor (1,041,961 for, 33,322 against, 238,766 abstain); 2,369,688 shares were outstanding as of the July 30, 2026 record date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2079272/000121390026104177/0001213900-26-104177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2079272/000121390026104177/ea0306660-8k_lakewood.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-104177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer